# Why Do People Turn Down a GLP-1 Prescription? What One Study Found

In one weight program, 57 of 78 people offered liraglutide declined. The study identified out-of-pocket cost as the main reason.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/why-do-people-turn-down-a-glp1-prescription
Updated: 2026-11-14
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# Why Do People Turn Down a GLP-1 Prescription? What One Study Found

In a supervised weight program, 57 of 78 people offered liraglutide declined. The researchers reported out-of-pocket cost as the main reason.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

78 people were offered the drug · 21 started it · 57 declined — mainly the out-of-pocket cost · Average loss: 3.2% among starters, 1.4% among decliners. · Six-week follow-up in a supervised weight program.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   In one supervised weight program, 57 of 78 people offered liraglutide declined. The study reported out-of-pocket cost as the main reason.
-   The 21 people who started liraglutide lost an average of 3.2% over six weeks. Those who declined lost 1.4%. Participants chose whether to start treatment.
-   In a Swedish survey, 69% of responding primary care doctors identified high patient copayments as a barrier. The survey ran during supply shortages.

When you use the [GLP-1 cost guide](https://buythisglp.com/research/how-much-does-a-glp1-cost-per-month) to compare quotes, check what you would owe after coverage and what the same prescription would cost at renewal. In one supervised weight program, out-of-pocket cost was the main reason people declined liraglutide [\[1\]](https://buythisglp.com/research/why-do-people-turn-down-a-glp1-prescription#ref-1). The study did not establish a refusal rate across all GLP-1 prescriptions.

## Who was offered liraglutide

The 12-week program enrolled 174 adults with obesity. At week six, the researchers offered liraglutide to the 78 participants who had lost less than 2.5% of their starting weight. Twenty-one agreed to start and 57 declined.

Over the next six weeks, those who started lost an average of 3.5 kg (3.2%), compared with 1.3 kg (1.4%) among those who declined (P<0.001). Four participants reported nausea and two reported upper abdominal pain.

Participants chose whether to start treatment

The researchers adjusted for body mass index, age, sex, and earlier weight change. People who chose treatment may have differed in other ways, so the comparison cannot establish how much of the difference was due to liraglutide.

## What national data say about access

A separate analysis of U.S. Medical Expenditure Panel Survey data from 2017 to 2023 measured use of GLP-1 receptor agonists and SGLT2 inhibitors together [\[2\]](https://buythisglp.com/research/why-do-people-turn-down-a-glp1-prescription#ref-2). If coverage is uncertain, the [insurance worksheet](https://buythisglp.com/tools/glp1-insurance-worksheet) helps you check the formulary and record any approval requirements. The survey measured medication use across both drug classes and cannot tell you how often people turned down a GLP-1 prescription.

## What Swedish doctors reported

A 2024 survey in five Swedish regions received 190 responses, a response rate of 28%, and analyzed 163 [\[3\]](https://buythisglp.com/research/why-do-people-turn-down-a-glp1-prescription#ref-3). During that survey, 86% identified supply shortages and 69% identified high patient copayments as prescribing barriers. The figures describe the responding doctors during that period.

## Starting and staying on treatment

The research on [why people stop taking a GLP-1](https://buythisglp.com/research/why-do-people-stop-taking-a-glp1) examines patients who had already begun treatment. The liraglutide study captured an earlier decision, when participants were first offered the prescription.

## Frequently asked

Why did people decline liraglutide in the study?

Out-of-pocket cost was the main reason the researchers reported. In the supervised program, 57 of 78 people offered liraglutide declined.

How did weight change among people who started?

Those who started lost an average of 3.2% over the next six weeks, compared with 1.4% among those who declined. Participants chose whether to start, so the study cannot establish how much of the difference was due to medication.

Does that refusal rate apply to other GLP-1 prescriptions?

The rate comes from one program that offered liraglutide to people who had lost less than 2.5% of their starting weight by week six. It cannot establish how many patients decline other prescriptions.

## Sources

1.  \[1\] Gilardini L, et al. (2026). Effectiveness of Liraglutide in Patients With Obesity Who Are Early Non-Responders to Lifestyle Intervention: A Real-World Study Journal of Obesity. [PMID 42658045](https://pubmed.ncbi.nlm.nih.gov/42658045/)
2.  \[2\] Jacobs M, Fang Q, Ellis C (2026). Trends in GLP-1 Receptor Agonist and SGLT2-Inhibitor Utilization and Expenditure Between 2017-2023: Demographic, Income, and Insurance Associations Journal of General Internal Medicine. [PMID 41984414](https://pubmed.ncbi.nlm.nih.gov/41984414/)
3.  \[3\] Sundell I, Wettermark B, Sundström A, Martinell M, Ericsson B (2026). Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey BMC Primary Care. [PMID 42557543](https://pubmed.ncbi.nlm.nih.gov/42557543/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
